Colorectal cancer, unlike other cancer types, is significantly influenced by dietary and lifestyle factors. Evaluating drug responsiveness based on specific genetic markers and MSI (microsatellite instability) in patients is crucial, and colorectal cancer organoids were developed to address these challenges.
Using the organoids, we observed that they better simulated patient diversity compared to traditional 2D cell lines and were more convenient to use than mouse xenograft models. This approach not only enhances the relevance of drug testing but also streamlines the experimental process.
Moving forward, we plan to utilize these organoids in various internal projects and research initiatives, further advancing our understanding and development of effective treatments for colorectal cancer.